Harvard Bioscience (HBIO, Financial) experienced a significant stock price increase of 5.56%, reaching $2.28 per share. The trading volume recorded was 120,363 shares with a turnover rate of 0.28% and a price fluctuation of 4.63%.
Recent financial reports indicate that Harvard Bioscience generated a revenue of $21.97 million, with a net loss of $4.80 million, resulting in an earnings per share (EPS) of -$0.11. The gross profit stood at $11.43 million, and the price-to-earnings (P/E) ratio was -6.82. Analyst ratings are favorable, with both participating institutions recommending a buy, and no hold or sell recommendations.
Within the medical equipment industry, where Harvard Bioscience operates, the sector saw an overall decline of 0.43%. Notable gainers in related stocks included Innovative Eyewear Inc, Milestone Scientific, Inc., and Pro-Dex, Inc. Meanwhile, Glucotrack, Inc., Bionano Genomics, Inc., and Sharps Technology Inc. showed high trading activity with turnover rates of 4.29%, 2.11%, and 1.62%, respectively. Stocks with significant price fluctuations included Nexgel Inc, Milestone Scientific, Inc., and Zhongjin Medical, with volatility rates of 19.61%, 14.72%, and 14.02% respectively.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technology and specialized products that support basic research, discovery, and preclinical testing in drug development. The company focuses on scientific instruments for life science research and operates in North America, Europe, and China, selling products globally through direct and distribution channels. Its product brands include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab, with most revenue generated from the U.S.
